Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$50.53M+31.31%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mihael H. Polymeropoulos
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 533
- Beta
- 0.69
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -1.58
Financials
Revenue
$50.53M+31.3%Net Income
$-62.51MEBITDA
$-61.53M-2552.3%Free Cash Flow
$-81.70M-12825.7%EPS (diluted)
$-1.04Shares Outstanding (diluted)
60.23M+38.4%Operating Expenses
$108.79MCash & Debt
$170.03MRevenue by Segment (annual)
$188.73MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $216.10M | $-220.47M | $-3.74 |
| 2024 | $198.77M | $-18.90M | $-0.32 |
| 2023 | $192.64M | $2.51M | $0.04 |
| 2022 | $254.38M | $6.28M | $0.11 |
| 2021 | $268.68M | $33.15M | $0.60 |
| 2020 | $248.17M | $23.34M | $0.43 |
| 2019 | $227.19M | $115.55M | $2.17 |
| 2018 | $193.12M | $25.21M | $0.50 |
| 2017 | $165.08M | $-15.57M | $-0.35 |
| 2016 | $146.02M | $-18.01M | $-0.41 |
| 2015 | $109.92M | $-39.87M | $-0.94 |
| 2014 | $50.16M | $20.19M | $0.58 |
| 2013 | $33.88M | $-20.25M | $-0.67 |
| 2012 | $32.73M | $-27.66M | $-0.98 |
Valuation
VNDAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
135+268.18%Social Signal Score
Mentions (6)
- Newsreuters.com·4d ago·Negative
Vanda says anxiety drug failed main goal of late-stage study, puts program on hold Vanda says anxiety drug failed main goal of late-stage study, puts program on hold
View source ↗ - Newsprnewswire.com·4d ago·Neutral
…ary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its clinical development program for VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist. Vanda's Phase III clinical study, VP-VQW-765-3201 (Study 3201), which evaluated VQW-765 for the on-demand treatment of acute anxiety in adults with social anxiety…
View source ↗ - Newsprnewswire.com·16d ago·Negative
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, being held in Vienna, Austria, from September 30 through October 3, 2026. The following will be presented: Presentation Title: "Rapid reduction in neutrophils and neutrophil percentage-to-albumin ratio upon treatment with imsidolimab in…
View source ↗ - Newsprnewswire.com·19d ago·Negative
…icipants shifted sleep at least 30 minutes earlier, compared to 15% of the placebo arm WASHINGTON, Sept. 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD).
View source ↗ - Newsprnewswire.com·46d ago·Neutral
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in September 2026: The Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026.
View source ↗ - Newsprnewswire.com·55d ago·Negative
… for the Treatment of Generalized Pustular Psoriasis by the European Commission WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European Commission, based on the positive opinion received from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, …
View source ↗
Earnings
Wed, Nov 4(in 2 weeks)
Consensus estimate $-0.72 per share
Typical surprise -22.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-1.04 vs $-0.58miss
- Wed, May 6$-0.82 vs $-0.53miss
- Wed, Feb 11$-2.39 vs $-2.18miss
- Wed, Oct 29$-0.38 vs $-0.31miss
- Thu, Jul 31$-0.46 vs $-0.34miss
- Wed, May 7$-0.50 vs $-0.55beat
Estimates and results for VNDA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VNDA officers and directors.
- Bought
- $514k
- Sold
- $3.4m
15 trades
20 trades
- Williams Timothysold
- Moran Kevin Patricksold
- Wijkstrom Joakimsold
- Polymeropoulos Mihael Hristossold
- Birznieks Gunthersold
- Honore Tagesold
- Polymeropoulos Mihael Hristosbought
- Mitchell Stephen Raysold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VNDA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.